Emicizumab: a novel drug in hemophilia A prophylaxis – a narrative review
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2131526
Abstract: ABSTRACT Introduction Hemophilia A is a genetically conditioned disease leading to hemostatic disorders due to factor VIII (FVIII) deficiency. The treatment of hemophilia has evolved throughout the past years and has significantly changed. One of… read more here.
Keywords: hemophilia prophylaxis; review; factor; emicizumab novel ... See more keywords